Use of proton pump inhibitors in adults in France: a nationwide drug utilization study.
Purpose: Proton pump inhibitor (PPI) drugs are approved for the management of gastric acid–related diseases, mainly treatment of gastroesophageal reflux disease, treatment of nonsteroidal anti-inflammatory drugs (NSAID)–related gastrointestinal complications and prevention in at-risk patients, Helic...
| Publicado en: | European Journal of Clinical Pharmacology Vol. 76; no. 3; pp. 449 - 458 |
|---|---|
| Autores principales: | , , , , , , , , |
| Formato: | research tables/charts Journal Article |
| Publicado: |
Springer Nature
Mar2020
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=141663158&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 141663158 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 00316970 NP9 jtl: European Journal of Clinical Pharmacology issn: 00316970 maglogo: N pubinfo: dt: Mar2020 vid: 76 iid: 3 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 141663158 141663158 141663158 10.1007/s00228-019-02810-1 141663158 ppf: 449 ppct: 9 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Use of proton pump inhibitors in adults in France: a nationwide drug utilization study. aug: au: Lassalle, Marion Le Tri, Thien Bardou, Marc Biour, Michel Kirchgesner, Julien Rouby, Frank Dumarcet, Nathalie Zureik, Mahmoud Dray-Spira, Rosemary affil: EPI-PHARE, Epidemiology of Health Products (French National Agency for the Safety of Medicines and Health Products [ANSM], and French National Health Insurance [CNAM]), Saint-Denis, France sug: subj: Gastrointestinal Diseases Drug Therapy Proton Pump Inhibitors Therapeutic Use Drug Utilization In Adulthood Human France Adult Descriptive Statistics Male Female Middle Age Adult: 19-44 years Middle Aged: 45-64 years Male Female ab: Purpose: Proton pump inhibitor (PPI) drugs are approved for the management of gastric acid–related diseases, mainly treatment of gastroesophageal reflux disease, treatment of nonsteroidal anti-inflammatory drugs (NSAID)–related gastrointestinal complications and prevention in at-risk patients, Helicobacter pylori eradication, and treatment of ulcers. PPIs are one of the most commonly prescribed drug class worldwide, and off-label use is widespread. The aim of this study was to describe outpatient PPI use of the whole adult population in France, based on the French National Health Data System (SNDS). Methods: All individuals aged 18 years or older, with at least one dispensing for PPI between January 1, 2015 and December 31, 2015, were identified as PPI users. PPI users were considered as new users if they received no dispensing for PPI in the prior year. New users were followed until treatment discontinuation or up to 1 year, whichever occurred first. Characteristics of new users and of their PPI treatment were described, overall and separately by treatment indication. Results: In total, 15,388,419 PPI users were identified in 2015 (57.0% women; mean age 57.0 years), accounting for 29.8% of the French adult population. Of them, 7,399,303 were new PPI users; mean treatment duration was 40.9 days, and 4.1% received a continuous PPI therapy lasting more than 6 months (10.2% among new users > 65 years versus 2.4% among those 18–65 years). For 53.5% of new users, indication for PPI therapy was a co-prescription with NSAID; in this indication, the large majority of patients (79.7%) had no measurable risk factor supporting a systematic prophylactic co-prescription of PPI. A proportion of 32.4% of new users did not have any identified comedication or inpatient diagnosis supporting an indication for PPI therapy; among them, only a small proportion (7.3% overall, and 8.4% of patients aged > 65 years) underwent a procedure investigating the digestive tract at the time of PPI initiation. Conclusion: The results of this study suggest PPI overuse in France, not always in line with the French guidelines. In particular, inappropriate co-prescription with NSAID was frequent. Efforts should be made to limit PPI treatment to appropriate indications and durations. pubtype: Academic Journal doctype: research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|